Showing 1 - 10 of 34
Persistent link: https://www.econbiz.de/10001849939
This paper is part of the project European Integration, Financial Systems and Corporate Performance (EIFC) carried out within the European Commission s specific programme Improving the Human Research Potential and the Socio-Economic Knowledge Base . Financial support from the European Union, DG...
Persistent link: https://www.econbiz.de/10001748811
Persistent link: https://www.econbiz.de/10001749135
Persistent link: https://www.econbiz.de/10013260912
This paper studies the evolution of early retirement due to disease and injury in the German labor force between 1988 and 2004. Using data from the German Federation of Public Pension Providers, the IMS Health Drug Launches database and the WHO Mortality Database, we show that new drug launches...
Persistent link: https://www.econbiz.de/10003449223
Based on the aggregation of individual willingness-to-pay for a statistical life, we calibrate an intertemporal optimization model to determine the aggregate welfare losses from HIV/AIDS in 25 Eastern European countries. Assuming a discount rate of three percent, we find a total welfare loss for...
Persistent link: https://www.econbiz.de/10003375874
Several experimental studies observed substantial violations of transitivity in decisions between risky lotteries over monetary outcomes. The goal of our experiment is to test whether these violations also affect the evaluation of health states. A particular feature of our experimental design is...
Persistent link: https://www.econbiz.de/10003665684
This study investigates the role of stratification of health and income in the social cost of health-related early retirement, as evidenced in the German Socio-economic Panel (GSOEP). We interpret early retirement as a mechanism to limit work-related declines in health that allows poorer and...
Persistent link: https://www.econbiz.de/10003670498
Persistent link: https://www.econbiz.de/10009785440
This paper discusses alternative incentive mechanisms for encouraging pharmaceutical innovations that support global health policy priorities. Patent buyouts, in which a public fund pays a mark-up on private valuations from sealed-bid second-price auctions, would boost the efficiency of research...
Persistent link: https://www.econbiz.de/10011490432